{
    "root": "0823087f-bdff-4578-b259-cc6062dfc991",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex sodium",
    "value": "20250328",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 750000 MW)",
            "code": "P2OM2Q86BI"
        },
        {
            "name": "ETHYLCELLULOSE (7 MPA.S)",
            "code": "H3UP11403C"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYPROMELLOSE 2208 (100000 MPA.S)",
            "code": "VM7F0B23ZI"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Divalproex sodium extended-release tablets are indicated for: • Acute treatment of manic or mixed episodes associated with      bipolar disorder, with or without psychotic features ( 1.1 ) • Monotherapy and adjunctive therapy of complex partial      seizures and simple and complex absence seizures; adjunctive therapy in patients      with multiple seizure types that include absence seizures ( 1.2) • Prophylaxis of migraine headaches ( 1.3)",
    "contraindications": "• Divalproex sodium extended-release tablets are intended      for once-a-day oral administration. Divalproex sodium extended-release      tablets should be swallowed whole and should not be crushed or chewed      ( 2.1 , 2.2 ). • Mania: Initial dose is 25 mg/kg/day, increasing as rapidly      as possible to achieve therapeutic response or desired plasma level (2.1).      The maximum recommended dosage is 60 mg/kg/day      ( 2.1 , 2.2 ). • Complex Partial Seizures: Start at 10 to 15 mg/kg/day,      increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal      clinical response; if response is not satisfactory, check valproate plasma      level; see full prescribing information for conversion to monotherapy      ( 2.2 ). The maximum recommended dosage is 60      mg/kg/day ( 2.1 , 2.2 ). • Absence Seizures: Start at 15 mg/kg/day, increasing at 1      week intervals by 5 to 10 mg/kg/day until seizure control or limiting side      effects (2.2). The maximum recommended dosage is 60 mg/kg/day      ( 2.1 , 2.2 ). • Migraine: The recommended starting dose is 500 mg/day for      1 week, thereafter increasing to 1,000 mg/day      ( 2.3 ).",
    "warningsAndPrecautions": "Divalproex sodium extended-release tablets USP, 500 mg are available as grey colored, oval shaped, film coated tablets, imprinted \"L089\" on one side and plain on the other side. Each divalproex sodium extended-release tablet contains divalproex sodium equivalent to 500 mg of valproic acid in the following packaging sizes:\n                  Bottle of 30                 (NDC 68788-8358-3)\n                  Bottle of 60                 (NDC 68788-8358-6)\n                  Bottle of 90                 (NDC 68788-8358-9)\n                  \n                     \n                        Recommended Storage\n                     \n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Dispense in a USP tight, light-resistant container.",
    "adverseReactions": "• Hepatic disease or significant      hepatic dysfunction ( 4 , 5.1 ) • Known mitochondrial disorders      caused by mutations in mitochondrial DNA polymerase γ (POLG)      ( 4 , 5.1 ) • Suspected POLG-related      disorder in children under two years of age ( 4 , 5.1 ) • Known hypersensitivity to the      drug ( 4 , 5.12 ) • Urea cycle disorders      ( 4 , 5.6) • Prophylaxis of migraine      headaches: Pregnant women, women of childbearing potential not using      effective contraception ( 4 , 8.1 )"
}